Testing Latest Version of NidekRS3000Adv

July 6, 2018 updated by: Kenneth Marion, Doheny Image Reading Center
The investigators would like to know if different imaging devices can improve the quality of images and visualization of imaged tissues. Also, the investigators would like to find out whether these changes are useful in the diagnosis and treatment of eye diseases. Using images of previous participants will allow us to demonstrate the advancement of different technologies, as well be used to allow comparisons between current technologies.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Pasadena, California, United States, 91105
        • Doheny Eye Centers UCLA

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Control subjects with no ocular problems, with whom no record review will be conducted, but imaging will be conducted with study devices.

Description

Inclusion Criteria:

  • Healthy participants
  • 18 years old or older

Exclusion Criteria:

  • Those suffering from head, neck or other injury which makes them unable to position themselves in head restraint for imaging
  • subjects who are unable to maintain retinal fixation on a specified target
  • subjects unable to achieve sufficient pupil dilation and alignment stability for imaging to take place
  • subjects with media opacity which preclude high quality imaging will be excluded.
  • vulnerable subjects
  • subjects under 18
  • pregnant subjects
  • economically and educationally disadvantaged subjects
  • decision impaired subjects
  • homeless subjects

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ocular vascularization
Time Frame: 1 year
Nidek RS3000Adv device to be used to take images which will allow measurement of vascularization in participants
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Srinivas Sadda, MD, Doheny Eye Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2018

Primary Completion (Actual)

March 28, 2018

Study Completion (Actual)

March 28, 2018

Study Registration Dates

First Submitted

October 19, 2017

First Submitted That Met QC Criteria

October 19, 2017

First Posted (Actual)

October 24, 2017

Study Record Updates

Last Update Posted (Actual)

July 9, 2018

Last Update Submitted That Met QC Criteria

July 6, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIDEKRS3000ADV

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glaucoma

3
Subscribe